Russell Dahl ’97, CEO and Founder of Neurodon Corporation has entered into a 2-year partnership with JDRF to discover new therapeutic candidates to treat type 1 diabetes (T1D). The project builds on Dr. Dahl’s pioneering work developing molecules that alleviate a condition known as endoplasmic reticulum stress, a key driver of beta cell dysfunction and loss in T1D. Also participating in the collaboration are the Indiana University School of Medicine and the Universite Libre de Bruxelles.

17 Aug 2022